After raising $100M, Google-backed Evelo looks to blaze a new trail with monoclonal microbials
Simba Gill has always wanted, in his own words, “to build one great, fully-integrated biotech company.”
And now he’s taking his shot with Evelo Biosciences.
Today, Gill and his crew of 50 are taking the wraps off a $50 million investment round, which brings the total raised so far to $100 million. That’s enough money for Evelo — an early-stage combination of two fledglings incubated by Flagship Pioneering that were both tackling the same objective from opposite ends of the disease spectrum — to take a giant step into the clinic with a slate of at least five programs that will each look to demonstrate that a particular microbial strain can act to accelerate or brake an immune system attack.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.